#USA #Milford #Waters Corporation #Diagnostic Solutions #Biosciences

Waters Corporation Reports Robust Financial Results for Q2 2026

Waters Corporation (NYSE: WAT) has unveiled its financial performance for the second quarter of 2026, revealing a total revenue of $1.645 billion. This figure prominently eclipses the previously established guidance range, signifying an extraordinary period of growth across both organic revenues and newly acquired businesses.

Strong Revenue Growth

This quarter, the company’s organic revenue reached $828 million, signifying a 7% increase from the previous year; when adjusted for constant currency, the growth accelerates to 9%. This performance includes an impressive growth rate of 8% within the Analytical Sciences Division (ASD) and a notable double-digit increase in chemistry consumables, particularly in pharmaceutical and agricultural sectors.

The revenue from the Biosciences and Diagnostic Solutions segment tallied $817 million, surpassing expectations by $15 million. With a 4% increase on a comparable prior year basis, this reflects Waters’ effective commercial strategies and ongoing operational adjustments under its 180-day growth revitalization initiative.

Financial Metrics

In terms of earnings, the company recorded a GAAP loss per share of $1.39, attributed to acquisition-related costs. Meanwhile, the adjusted earnings per share settled at $3.05, positioning it at the upper end of the guidance spectrum, buoyed by early cost management plays that mitigated adverse currency translation effects.

Dr. Udit Batra, President and CEO, remarked, "With the ongoing efforts from our committed teams, we’ve achieved notable growth across all divisions this quarter, exceeding forecasts. The organic revenue growth of 9% in constant currency, coupled with significant contributions from our recent acquisitions in their inaugural quarter, highlights our effective integration and market recovery which has broadened across several customer segments."

Revised Guidance for the Year

Given the robust performance in the second quarter, Waters Corporation has revised its full-year 2026 expectations upwards. The firm anticipates organic constant currency revenue growth to be in the 7% to 9% range and projects acquired business revenue at approximately $3.045 billion. Additionally, they predict adjusted earnings per share to fall between $14.45 to $14.65, reflecting an impressive year-on-year growth rate.

Segment Performance Overview

Analytical Sciences Division (ASD)

The ACS segment generated $669 million in revenue for Q2 2026, a notable increase from $627 million in the prior year.

Biosciences Division (WBD)

Reported revenue stood at $368 million, showing consistent growth compared to $358 million previously.

Advanced Diagnostics Division (ADx)

This segment delivered revenue of $449 million, up from $425 million over the same comparison period. The Clinical Business Unit separately generated $72 million, reflecting a year-on-year growth from $62 million.

Materials Sciences Division (MSD)

The MSD recorded $87 million in revenue, slightly advancing from $82 million in Q2 2025.

Looking Ahead

As Waters Corporation forges ahead, Dr. Batra emphasizes that the company is strategically positioned for sustained growth, bolstered by solid market conditions and a resolute focus on integration and synergies from recent acquisitions.

Waters Corporation will host a conference call today to further discuss the second quarter results, accessible via the investor relations section on their website.

In conclusion, the financial outcomes reported signify not only a promising rebound following the pandemic but also reiterate Waters Corporation's dedicated efforts to propel itself within the life sciences and diagnostics industry through both organic growth and strategic acquisitions. As their integration strategies continue to flourish, Waters is poised to maintain its trajectory towards becoming a more robust entity capable of delivering innovative solutions in analytical technologies.